通过测定游离前列腺特异性抗原百分比提高前列腺癌与良性前列腺增生的鉴别诊断能力
[Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
作者信息
Wolff J M, Borchers H, Boeckmann W, Habib F K, Jakse G
机构信息
Urologische Klinik, RWTH Aachen.
出版信息
Urologe A. 1997 May;36(3):255-8. doi: 10.1007/s001200050100.
We investigated whether the free-to-total prostate-specific antigen (PSA) ration (f-PSA/t-PSA ratio; i.e. percentage of free PSA) represents a better discriminator for the detection of cancer of the prostate (CaP). In a retrospective analysis, the percentage of free PSA was determined in the sera of 35 patients with histologically proven benign prostatic hyperplasia (BPH) and 35 patients with clinically localized CaP. Patients with urolithiasis (n = 33) served as a control group. Serum levels of free PSA and total PSA were determined employing a chemiluminescent enzyme immunoassay. Patients with CaP demonstrated a lower percentage of free PSA (median: 8.7) than patients with BPH (median: 20.0; P < 0.001). Determination of the percentage of free PSA enhances the differentiation between BPH and CaP and may reduce the number of unnecessary biopsies in patients with an elevated PSA. Confirmation of our preliminary results is required.
我们研究了游离前列腺特异性抗原（PSA）与总前列腺特异性抗原的比值（f-PSA/t-PSA比值，即游离PSA的百分比）是否能更好地区分前列腺癌（CaP）。在一项回顾性分析中，测定了35例经组织学证实为良性前列腺增生（BPH）患者和35例临床局限性CaP患者血清中的游离PSA百分比。33例尿路结石患者作为对照组。采用化学发光酶免疫分析法测定血清游离PSA和总PSA水平。CaP患者的游离PSA百分比（中位数：8.7）低于BPH患者（中位数：20.0；P<0.001）。测定游离PSA百分比可增强BPH与CaP之间的鉴别能力，并可能减少PSA升高患者不必要的活检次数。我们的初步结果需要进一步证实。
Zotero 插件